Expanding access to vascular care using BlueDop Vascular Expert: an artificial intelligence-driven diagnostic tool
Journal of Wound Care · 01.06.2026 · 35 (Sup6a)
DOI: 10.12968/jowc.2025.0595 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Wound Care, erschienen am 01.06.2026. Verfasst von Ben J Van Bockern und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of South Dakota Sanford School of Medicine, Sioux Falls, SD, US. Hauptthemen laut MEDLINE: Peripheral Arterial Disease, Ankle Brachial Index, Artificial Intelligence. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Objective
This study aimed to evaluate and compare the screening capabilities of BlueDop Vascular Expert (BVE; BlueDop Medical Ltd., UK) and the ankle–brachial index (ABI) in detecting peripheral arterial disease (PAD) among a diverse patient population, including those with a history of smoking, obesity, diabetes and hypertension.
Method
This prospective study used data from two separate studies; a current single-centre cohort and a previously published dataset by Tessendorf et al. Data from the current cohort was analysed independently and in combination with the study by Tessendorf et al. Individuals at risk for PAD underwent both ABI and BVE testing. Full leg arterial duplex interpreted by an independent vascular surgeon served as the reference standard. Subgroup analysis was undertaken to compare BVE and ABI capabilities among those with underlying comorbidities, such as diabetes, hypertension, tobacco use and obesity, as these factors affect PAD detection.
Results
For all patients in the combined dataset (new study: n=550 limbs assessed by BVE; previous study: n=201 limbs assessed by BVE; combined total: n=751 limbs assessed by BVE), overall BVE sensitivity was 82.5%, specificity was 93.9%, accuracy was 91.2% and κ=0.76. In contrast, ABI sensitivity was 58.3%, specificity was 87.4%, accuracy was 80.6%, and κ=0.46. Increased accuracy, sensitivity, specificity, and κ constant were present in all analysed subgroups when comparing BVE to ABI.
Conclusion
In this study, BVE provided more accurate and reliable PAD screening than ABI across diverse patient populations, including those with comorbidities that reduce ABI accuracy. Its portability, ease of use and minimal need for specialised interpretation support its use as a first-line screening tool, particularly in rural and underserved settings. Broader implementation of BVE could help reduce diagnostic disparities and improve outcomes for patients at risk for PAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of South Dakota Sanford School of Medicine, Sioux Falls, SD, US.
- University of Nebraska Medical Center College of Medicine, Omaha, NE, US.
- Dakota Vascular, Sioux Falls, SD, US.
- The Christ Hospital, Cincinnati, OH, US.
- Imperial College, London, UK.
Zitieren
APA
Bockern, B. J. V., Woldt, M. R., Devine, J. R., Withrow, A. D., Tessendorf, C. D., Bleeker, C., Ostrem, M., Answini, G. A., Al-Qaisi, M., & Kelly, P. W. (2026). Expanding access to vascular care using BlueDop Vascular Expert: an artificial intelligence-driven diagnostic tool. Journal of Wound Care, 35(Sup6a). https://doi.org/10.12968/jowc.2025.0595
Vancouver
Bockern BJV, Woldt MR, Devine JR, Withrow AD, Tessendorf CD, Bleeker C, et al. Expanding access to vascular care using BlueDop Vascular Expert: an artificial intelligence-driven diagnostic tool. Journal of Wound Care. 2026;35(Sup6a). doi:10.12968/jowc.2025.0595
BibTeX
@article{Bockern2026,
author = {Bockern, Ben J Van and Woldt, Mason R and Devine, Jacob R and Withrow, Alexander Dm and Tessendorf, Cole D and Bleeker, Chelsy and Ostrem, Melissa and Answini, Geoffrey A and Al-Qaisi, Mo and Kelly, Patrick W},
title = {Expanding access to vascular care using BlueDop Vascular Expert: an artificial intelligence-driven diagnostic tool},
journal = {Journal of Wound Care},
year = {2026},
volume = {35},
number = {Sup6a},
doi = {10.12968/jowc.2025.0595}
}
EUVIMED